Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Achaogen Inc (AKAO) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/28/2019 8-K Quarterly results
Docs: "Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update"
11/08/2018 8-K Quarterly results
Docs: "ZEMDRI Launch Update: The launch focus continues to be the education of physicians on the clinical profile of ZEMDRI and building the foundation to support product use across the hospital and outpatient settings. The commercial organization continues to build momentum on key leading indicators including: formulary review and approval, orders of antibiotic susceptibility testing materials and customer readiness for therapeutic drug management testing. ZEMDRI revenues for the quarter represent approximately two months of product sales prior to broad formulary approval or the availability of the NTAP supplementary reimbursement, which went into effect on October 1st. During the quarter, ZEMDRI achieved net revenues of $291,000 and, to date, 60% of use has been in the outpatient setting. &#x20..."
08/06/2018 8-K Quarterly results
Docs: "Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update"
05/04/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 4, 2018 ACHAOGEN, INC. Delaware 001-36323 68-0533693 1 Tower Place, Suite 300 South San Francisco, CA 94080 Registrant's telephone number, including area code: 800-3636 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communic...",
"Recent Highlights and Upcoming Milestones"
02/27/2018 8-K Quarterly results
Docs: "Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update"
11/08/2017 8-K Quarterly results
Docs: "Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update"
08/03/2017 8-K Quarterly results
05/08/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
03/15/2016 8-K Quarterly results
Docs: "Achaogen Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update -- Commenced Pivotal Phase 3 EPIC Study of Plazomicin in Complicated Urinary Tract Infections; Continue to Expect Top-Line Data and NDA Submission in the Second Half of 2017 -- -- Reduced Enrollment Target of Phase 3 CARE Study of Plazomicin in CRE Infections; Expect Top-Line Data from CARE in the Second Half of 2017 -- -- Conference Call Today at 8:30 a.m. Eastern Time -- South San Francisco, Calif., Mar. 15, 2016 - Achaogen, Inc. , a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today reported financial results for the fourth quarter and year ended December 31, 2015, and also provided an update on its corpo..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy